Screener
CytomX Therapeutics CTMX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
FAQ
- What is CytomX Therapeutics's total equity?
- CytomX Therapeutics (CTMX) reported total equity of $302.07M in Q2 2026.
- How has CytomX Therapeutics's total equity changed year-over-year?
- CytomX Therapeutics's total equity increased by 151.9% year-over-year, from $119.91M to $302.07M.
- What is the long-term trend for CytomX Therapeutics's total equity?
- Over 5 years (2020 to 2025), CytomX Therapeutics's total equity has grown at a 66.3% compound annual growth rate (CAGR), from -$7.77M to $99.01M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about CytomX Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude